pravastatin has been researched along with HIV Coinfection in 41 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 22 (53.66) | 29.6817 |
| 2010's | 17 (41.46) | 24.3611 |
| 2020's | 2 (4.88) | 2.80 |
| Authors | Studies |
|---|---|
| Alkaabi, M; Amoodi, AA; Baraka, MA; Don, J; Elnour, AA; Farah, FH; Mazrouei, NA; Ramadan, A; Sadeq, A; Sam, KG | 1 |
| Avihingsanon, A; Bautista-Arredondo, S; Bendavid, E; Boettiger, DC; Chaiwarith, R; Chattranukulchai, P; Kahn, JG; Khusuwan, S; Kiertiburanakul, S; Law, MG; Newall, AT; Phillips, A; Ross, J | 1 |
| Aberg, JA; Campbell, SE; Kryzhanovski, VA; Sponseller, CA; Thompson, MA; Ward, DJ | 1 |
| Alves Saldanha, S; Buclin, T; Cavassini, M; Courlet, P; Csajka, C; Decosterd, LA; Desfontaine, V; Marzolini, C; Spaggiari, D | 1 |
| Annoni, F; Caputo, S; Cremona, AM; Grandi, AM; Grossi, P; Guasti, L; Marchesi, C; Maresca, AM; Nicolini, E; Rizzi, L | 1 |
| Bansal, A; Burkholder, G; Goepfert, PA; Kahan, SM; Overton, ET; Sterrett, S; Westfall, AO; Zajac, AJ | 1 |
| Kietsiriroje, N; Leelawattana, R | 1 |
| Florence, E; Kenyon, C; Leys, J; Suttels, V; Van den Ende, J; Vekemans, M; Vlieghe, E | 1 |
| Aslangul, É; Assoumou, L; Bittar, R; Bonnefont-Rousselot, D; Cherfils, C; Costagliola, D; Federspiel, MC; Giral, P; Kalmykova, O; Valantin, MA | 1 |
| Chang, KC; Ko, NY; Li, CY; Ou, HT; Yang, CY | 1 |
| D'Agostino, RB; Jones, SR; Joshi, PH; Kulkarni, KR; Martin, SS; Massaro, JM; Miller, PE; Sponseller, C; Toth, PP | 1 |
| Aberg, JA; Burdo, TH; Fitch, KV; Grinspoon, SK; McCurdy Pate, M; Sanchez, L; Sponseller, CA; Toribio, M; Williams, KC; Zanni, MV | 1 |
| Calza, L; Chiodo, F; Colangeli, V; Manfredi, R; Pavoni, M; Pocaterra, D | 1 |
| Cope, D; Iskander, E; Mikhail, N | 1 |
| Aslangul, E; Assoumou, L; Bittar, R; Boccara, F; Bonnefont-Rousselot, D; Costagliola, D; Fiévet, MH; Giral, P; Kalmykova, O; Melchior, JC; Peytavin, G; Valantin, MA | 1 |
| Bergin, C; Moriarty, M; Nolan, DP; O'Connor, C; O'Connor, MB; O'Leary, A | 1 |
| Bloch, M; Calmy, A; Carr, A; Cooper, DA; Delhumeau, C; Finlayson, R; Hirschel, B; Norris, R; Rafferty, M; Wand, H | 1 |
| Auclair, M; Bastard, JP; Boccara, F; Capeau, J; Caron-Debarle, M; Lefèvre, C; Vigouroux, C | 1 |
| Aslangul, E; Assoumou, LK; Bastard, JP; Capeau, J; Costagliola, D; Fellahi, S | 1 |
| Aberg, JA; Evans, SE; Fichtenbaum, CJ | 1 |
| Baker, JV; Duprez, D; Grimm, R; Henry, K; Huppler Hullsiek, K; Neaton, JD; Prosser, R; Rhame, F; Tracy, RP | 1 |
| Buss, NE; Gazzard, BG; Moyle, GJ | 1 |
| Baiano, A; de Cristofaro, A; Del Forno, D; Giallauria, F; Paragliola, T; Rossi, M; Vigorito, C | 1 |
| Aller, R; Bachiller, P; de Luis, DA; Eiros Bouza, J; Izaola, O | 1 |
| Aeschlimann, SE; Bellehumeur, JL; Korcarz, CE; Mays, ME; Merwood, MA; Sosman, JM; Stein, JH; Underbakke, GL | 1 |
| Benesic, A; Klinker, H; Kluge, F; Langmann, P; Weissbrich, B; Winzer, R; Zilly, M | 1 |
| Béchir, M; Chenevard, R; Enseleit, F; Flepp, M; Hürlimann, D; Kobza, R; Ledergerber, B; Lüscher, TF; Muntwyler, J; Noll, G; Ruschitzka, F; Weber, R | 1 |
| Calza, L; Chiodo, F; Colangeli, V; Manfredi, R; Pocaterra, D; Sebastiani, T; Tampellini, L | 1 |
| Freed, EO; Grubb, JR; Maldarelli, F; Masur, H; Ono, A; Sklar, PA; Voell, J; Witek, J | 1 |
| Aberg, JA; Alston, BL; Brobst, SW; Fichtenbaum, CJ; Gerber, JG; Rosenkranz, SL; Segal, Y; Vega, JM; Yang, A | 1 |
| Aberg, JA; Alston, BL; Brobst, SW; Evans, SR; Fichtenbaum, CJ; Glesby, MJ; Henry, WK; Owens, SI; Torriani, FJ; Yang, Y; Zackin, RA | 1 |
| Carr, A; Cooper, DA; Feneley, MP; Kent-Hughes, J; Kovacic, JC; Mallon, PW; Miller, J; Norris, R; Samaras, K | 1 |
| Boccara, F; Capeau, J; Gharakhanian, S | 1 |
| Boccara, F; Boutouyrie, P; Bozec, E; Cohen, A; Durant, S; Girard, PM; Lacombe, K; Laloux, B; Laurent, S; Simon, T | 1 |
| Bennett, MT; Bondy, GP; Johns, KW | 1 |
| Bhalodia, J; Hollowell, SB; Johnson, MD; Kaye, KS; Townsend, ML; Wilson, KH | 1 |
| Gaughan, JP; Klibanov, OM; Tedaldi, EM; van den Berg-Wolf, M | 1 |
| Ammassari, A; Baldini, F; Cingolani, A; De Luca, A; Di Giambenedetto, S; Murri, R | 1 |
| Baldwin, C; Gazzard, BG; Lloyd, M; Mandalia, S; Moyle, GJ; Reynolds, B | 1 |
| Gathe, JC; Lahart, C; Stone, VE | 1 |
1 review(s) available for pravastatin and HIV Coinfection
| Article | Year |
|---|---|
A Systematic Review of Randomized Clinical Trials on the Efficacy and Safety of Pitavastatin.
Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Dyslipidemias; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Metabolic Syndrome; Pravastatin; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin | 2023 |
19 trial(s) available for pravastatin and HIV Coinfection
| Article | Year |
|---|---|
Pitavastatin versus pravastatin in adults with HIV-1 infection and dyslipidaemia (INTREPID): 12 week and 52 week results of a phase 4, multicentre, randomised, double-blind, superiority trial.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Anticholesteremic Agents; Cholesterol, LDL; Double-Blind Method; Dyslipidemias; Female; HIV Infections; Humans; Male; Middle Aged; Placebos; Pravastatin; Puerto Rico; Quinolines; Treatment Outcome; United States; Young Adult | 2017 |
Dyslipidemia in HIV-positive patients: a randomized, controlled, prospective study on ezetimibe+fenofibrate versus pravastatin monotherapy.
Topics: Adult; Anticholesteremic Agents; Azetidines; Drug-Related Side Effects and Adverse Reactions; Dyslipidemias; Ezetimibe; Female; Fenofibrate; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Pravastatin; Prospective Studies; Treatment Outcome | 2014 |
Effects of pravastatin, phytosterols, and combination therapy on lipid profile in HIV-infected patients: an open-labelled, randomized cross-over study.
Topics: Adult; Anticholesteremic Agents; Cholesterol, LDL; Cross-Over Studies; Drug Therapy, Combination; Female; HIV Infections; Humans; Hypercholesterolemia; Male; Middle Aged; Phytosterols; Pravastatin | 2015 |
Greater remnant lipoprotein cholesterol reduction with pitavastatin compared with pravastatin in HIV-infected patients.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Cholesterol; Double-Blind Method; Dyslipidemias; Female; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins; Male; Middle Aged; Pravastatin; Quinolines; Treatment Outcome; Ultracentrifugation; Young Adult | 2017 |
Effects of pitavastatin and pravastatin on markers of immune activation and arterial inflammation in HIV.
Topics: Anticholesteremic Agents; Arteritis; Biomarkers; Double-Blind Method; HIV Infections; Humans; Immunologic Factors; Pravastatin; Quinolines; Treatment Outcome | 2017 |
Rosuvastatin, pravastatin, and atorvastatin for the treatment of hypercholesterolaemia in HIV-infected patients receiving protease inhibitors.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Cholesterol; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; HIV Infections; HIV Protease Inhibitors; Humans; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Viral Load | 2008 |
Rosuvastatin versus pravastatin in dyslipidemic HIV-1-infected patients receiving protease inhibitors: a randomized trial.
Topics: Adult; Anticholesteremic Agents; Cholesterol, LDL; Dyslipidemias; Female; Fluorobenzenes; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Pravastatin; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Viral Load | 2010 |
No significant effect of uridine or pravastatin treatment for HIV lipoatrophy in men who have ceased thymidine analogue nucleoside reverse transcriptase inhibitor therapy: a randomized trial.
Topics: Absorptiometry, Photon; Adiposity; Adult; Anti-Retroviral Agents; Anticholesteremic Agents; Dideoxynucleosides; Drug Therapy, Combination; Extremities; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Lopinavir; Male; Middle Aged; Pravastatin; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Uridine | 2010 |
Angiotensin converting enzyme inhibitor and HMG-CoA reductase inhibitor as adjunct treatment for persons with HIV infection: a feasibility randomized trial.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Blood Pressure; Cholesterol; Feasibility Studies; Female; Follow-Up Studies; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lisinopril; Male; Medication Adherence; Middle Aged; Placebos; Pravastatin; Treatment Outcome | 2012 |
Pravastatin does not alter protease inhibitor exposure or virologic efficacy during a 24-week period of therapy.
Topics: Anticholesteremic Agents; Antiretroviral Therapy, Highly Active; HIV Infections; HIV Protease Inhibitors; Humans; Hypercholesterolemia; Male; Pravastatin; Viremia | 2002 |
Effects of pravastatin on lipoproteins and endothelial function in patients receiving human immunodeficiency virus protease inhibitors.
Topics: Adult; Brachial Artery; Cholesterol; Cross-Over Studies; Double-Blind Method; Endothelium, Vascular; Female; HIV Infections; HIV Protease Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertriglyceridemia; Lipoproteins; Male; Pravastatin; Reverse Transcriptase Inhibitors; Triglycerides; Ultrasonography; Vasodilation | 2004 |
Lipid lowering therapy with fluvastatin and pravastatin in patients with HIV infection and antiretroviral therapy: comparison of efficacy and interaction with indinavir.
Topics: Adult; Anticholesteremic Agents; Antiretroviral Therapy, Highly Active; Fatty Acids, Monounsaturated; Female; Fluvastatin; HIV Infections; HIV Protease Inhibitors; Humans; Hypercholesterolemia; Indinavir; Indoles; Male; Middle Aged; Pravastatin; Prospective Studies; Treatment Outcome | 2004 |
Effects of statins on endothelial function and lipid profile in HIV infected persons receiving protease inhibitor-containing anti-retroviral combination therapy: a randomised double blind crossover trial.
Topics: Adult; Antiretroviral Therapy, Highly Active; Blood Flow Velocity; Brachial Artery; Cross-Over Studies; Double-Blind Method; Endothelium, Vascular; Female; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Pravastatin; Vasodilation | 2006 |
Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidaemia.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Bezafibrate; Cyclopropanes; Female; HIV Infections; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Nevirapine; Oxazines; Pravastatin; Protease Inhibitors; Reverse Transcriptase Inhibitors; Treatment Outcome | 2005 |
Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study.
Topics: Adult; Alkynes; Anti-HIV Agents; Atorvastatin; Benzoxazines; Cholesterol, LDL; Cyclopropanes; Drug Interactions; Female; Heptanoic Acids; HIV Infections; HIV Seronegativity; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Oxazines; Pravastatin; Pyrroles; Simvastatin | 2005 |
A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087.
Topics: Adult; Drug Therapy, Combination; Female; Fenofibrate; HIV Infections; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pravastatin; Treatment Outcome | 2005 |
Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men--a randomized, placebo-controlled study.
Topics: Adipose Tissue; Antiretroviral Therapy, Highly Active; Biomarkers; Blood Glucose; Body Composition; Cardiovascular Diseases; Cholesterol; Diet; Double-Blind Method; HIV Infections; HIV Protease Inhibitors; HIV-Associated Lipodystrophy Syndrome; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Insulin; Male; Middle Aged; Pilot Projects; Pravastatin; Triglycerides | 2006 |
Efficacy and tolerability of pravastatin for the treatment of HIV-1 protease inhibitor-associated hyperlipidaemia: a pilot study.
Topics: Adult; Anticholesteremic Agents; Drug Tolerance; Female; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Hyperlipidemias; Indinavir; Male; Nelfinavir; Pilot Projects; Pravastatin; Ritonavir; Saquinavir; Treatment Outcome | 2000 |
Dietary advice with or without pravastatin for the management of hypercholesterolaemia associated with protease inhibitor therapy.
Topics: Anticholesteremic Agents; Cholesterol, LDL; Combined Modality Therapy; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Hypercholesterolemia; Male; Pravastatin; Viral Load | 2001 |
21 other study(ies) available for pravastatin and HIV Coinfection
| Article | Year |
|---|---|
Statins for atherosclerotic cardiovascular disease prevention in people living with HIV in Thailand: a cost-effectiveness analysis.
Topics: Adult; Atherosclerosis; Cost-Benefit Analysis; Drug Costs; Female; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pravastatin; Quality-Adjusted Life Years; Quinolines; Thailand | 2020 |
UHPLC-MS/MS assay for simultaneous determination of amlodipine, metoprolol, pravastatin, rosuvastatin, atorvastatin with its active metabolites in human plasma, for population-scale drug-drug interactions studies in people living with HIV.
Topics: Amlodipine; Anti-HIV Agents; Atorvastatin; Chromatography, High Pressure Liquid; Drug Interactions; HIV Infections; Humans; Linear Models; Metoprolol; Pravastatin; Reproducibility of Results; Rosuvastatin Calcium; Sensitivity and Specificity; Tandem Mass Spectrometry | 2019 |
Effects of atorvastatin and pravastatin on immune activation and T-cell function in antiretroviral therapy-suppressed HIV-1-infected patients.
Topics: Anti-Retroviral Agents; Anticholesteremic Agents; Atorvastatin; Heptanoic Acids; HIV Infections; HIV-1; Humans; Immunologic Factors; Interferon-gamma; Lymphocyte Activation; Pravastatin; Pyrroles; Retrospective Studies; T-Lymphocyte Subsets; T-Lymphocytes | 2014 |
A 68-year old male presenting with rhabdomyolysis-associated acute kidney injury following concomitant use of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate and pravastatin/fenofibrate: a case report.
Topics: Acute Kidney Injury; Aged; Anti-HIV Agents; Anticholesteremic Agents; Drug Interactions; Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Fenofibrate; HIV Infections; Humans; Hypolipidemic Agents; Male; Pravastatin; Rhabdomyolysis | 2015 |
Lack of effects of statins on high-density lipoprotein subfractions in HIV-1-infected patients receiving protease inhibitors.
Topics: Adult; Cardiovascular Diseases; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, HDL; Male; Middle Aged; Pravastatin; Risk; Rosuvastatin Calcium | 2017 |
Intensive statin regimens for reducing risk of cardiovascular diseases among human immunodeficiency virus-infected population: A nation-wide longitudinal cohort study 2000-2011.
Topics: Adult; Cardiovascular Diseases; Dose-Response Relationship, Drug; Female; Follow-Up Studies; HIV; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Population Surveillance; Pravastatin; Retrospective Studies; Risk Assessment; Risk Factors; Taiwan; Treatment Outcome; Young Adult | 2017 |
Rhabdomyolysis in an HIV-infected patient on anti-retroviral therapy precipitated by high-dose pravastatin.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Deoxycytidine; Dyslipidemias; Emtricitabine; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Oligopeptides; Organophosphonates; Pravastatin; Pyridines; Rhabdomyolysis; Ritonavir; Tenofovir | 2009 |
HIV-associated dyslipidaemia among HIV antibody-positive patients in Ireland: prevalence and management strategies.
Topics: Anti-HIV Agents; Anticholesteremic Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Dyslipidemias; Gemfibrozil; HIV Infections; HIV Protease Inhibitors; Humans; Hypolipidemic Agents; Ireland; Pravastatin; Prevalence; Retrospective Studies | 2010 |
Premature senescence of vascular cells is induced by HIV protease inhibitors: implication of prelamin A and reversion by statin.
Topics: Acetylcysteine; Adult; Antioxidants; Case-Control Studies; Cell Proliferation; Cells, Cultured; Cellular Senescence; Coronary Vessels; Cyclin-Dependent Kinase Inhibitor p21; Drug Therapy, Combination; Endothelial Cells; Farnesyltranstransferase; HIV Infections; HIV Protease Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lamin Type A; Lopinavir; Metalloporphyrins; Methionine; Middle Aged; Nuclear Proteins; Oxidative Stress; Paris; Pravastatin; Protein Precursors; Pyrimidinones; Ritonavir; Time Factors; Tumor Suppressor Protein p53 | 2010 |
High-sensitivity C-reactive protein levels fall during statin therapy in HIV-infected patients receiving ritonavir-boosted protease inhibitors.
Topics: Anticholesteremic Agents; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Dyslipidemias; Female; HIV Infections; Humans; Male; Middle Aged; Pravastatin; Ritonavir | 2011 |
High-sensitivity C-reactive protein levels do not decrease with the use of statins in all persons with HIV infection.
Topics: C-Reactive Protein; Cardiovascular Diseases; Dyslipidemias; Female; HIV Infections; Humans; Male; Pravastatin; Ritonavir | 2011 |
[Cardiac rehabilitation in a HIV-patient treated with protease inhibitors].
Topics: Adult; Aspirin; Carbazoles; Carvedilol; Cholesterol; Coronary Angiography; Diet Therapy; Drug Therapy, Combination; Enalapril; Exercise Therapy; HIV Infections; Humans; Male; Myocardial Infarction; Nitrates; Pravastatin; Propanolamines; Protease Inhibitors; Treatment Outcome; Triglycerides | 2003 |
Pravastatin in hyperlipidemia secondary to HIV protease inhibitors without response to fenofibrate: a brief preliminary report.
Topics: Adult; Anticholesteremic Agents; Female; Fenofibrate; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Pravastatin; Treatment Outcome | 2003 |
Pravastatin does not have a consistent antiviral effect in chronically HIV-infected individuals on antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; Anticholesteremic Agents; Cholesterol; Female; HIV Infections; Humans; Male; Pravastatin; Viral Load; Viremia | 2005 |
Statins in HIV-associated lipodystrophy and metabolic syndrome: is there a missing link?
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol; HIV Infections; HIV Protease Inhibitors; HIV-Associated Lipodystrophy Syndrome; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Metabolic Syndrome; Pravastatin; Treatment Outcome | 2006 |
Influence of pravastatin on carotid artery structure and function in dyslipidemic HIV-infected patients receiving antiretroviral therapy.
Topics: Age Factors; Anticholesteremic Agents; Antiretroviral Therapy, Highly Active; Aorta; Blood Pressure; Body Mass Index; Carotid Artery, Common; Female; HIV Infections; Humans; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Time Factors; Treatment Outcome; Tunica Intima | 2006 |
Ezetimibe is effective when added to maximally tolerated lipid lowering therapy in patients with HIV.
Topics: Adult; Aged; Anti-Retroviral Agents; Anticholesteremic Agents; Apolipoprotein B-100; Atorvastatin; Azetidines; Cholesterol; Ezetimibe; Female; Fluorobenzenes; Heptanoic Acids; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Pravastatin; Protease Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Triglycerides | 2007 |
A comparison of the effectiveness of lipid-lowering therapy between HIV- and non-HIV-infected subjects with hyperlipidaemia.
Topics: Adult; Aged; Cholesterol; Clofibric Acid; Cohort Studies; Female; Fish Oils; HIV Infections; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pravastatin; Treatment Outcome; Triglycerides | 2007 |
Ezetimibe combined with low-dose statin effectively lowers LDL in protease inhibitor treated patients.
Topics: Adult; Anticholesteremic Agents; Antiretroviral Therapy, Highly Active; Atorvastatin; Azetidines; Cholesterol, LDL; Drug Administration Schedule; Ezetimibe; Female; Follow-Up Studies; Heptanoic Acids; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Hypercholesterolemia; Lopinavir; Male; Middle Aged; Pilot Projects; Pravastatin; Prospective Studies; Pyrroles; Ritonavir; Treatment Outcome | 2008 |
Transplanted livers and kidneys for HIV+ people.
Topics: Antiretroviral Therapy, Highly Active; Cyclosporine; Hepatitis B; Hepatitis C; HIV Infections; Humans; Hypolipidemic Agents; Kidney Transplantation; Liver Failure; Liver Transplantation; Lovastatin; Pravastatin; Renal Insufficiency; San Francisco | 2001 |
Three HIV-treating physicians express their professional opinions regarding a case scenario.
Topics: CD4 Lymphocyte Count; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV Wasting Syndrome; Humans; Hypercholesterolemia; Male; Middle Aged; Practice Patterns, Physicians'; Pravastatin; Reverse Transcriptase Inhibitors; Viral Load | 2000 |